BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 466.19 Million SEK | 18.53% |
| 2022 | 476.88 Million SEK | 39.93% |
| 2021 | 276.86 Million SEK | 12.96% |
| 2020 | 248.83 Million SEK | -3.75% |
| 2019 | 258.52 Million SEK | -9.46% |
| 2018 | 282.95 Million SEK | 16.53% |
| 2017 | 240.41 Million SEK | 21.26% |
| 2016 | 202.08 Million SEK | 28.66% |
| 2015 | 177.63 Million SEK | -19.38% |
| 2014 | 194.82 Million SEK | 128.14% |
| 2013 | 85.39 Million SEK | -80.37% |
| 2012 | 435.04 Million SEK | 301.78% |
| 2011 | 114.29 Million SEK | 49.1% |
| 2010 | 71.32 Million SEK | 26.7% |
| 2009 | 56.73 Million SEK | 65.4% |
| 2008 | 32.84 Million SEK | 135.07% |
| 2007 | 14.67 Million SEK | 102.57% |
| 2006 | 6.23 Million SEK | 147.31% |
| 2005 | -15.38 Million SEK | -155.13% |
| 2004 | -20.11 Million SEK | 42.3% |
| 2003 | 19.6 Million SEK | -58.61% |
| 2002 | 47.37 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 160.88 Million SEK | 67.17% |
| 2024 Q2 | 147.33 Million SEK | -8.43% |
| 2024 Q3 | 106.82 Million SEK | -27.5% |
| 2023 FY | - SEK | 18.53% |
| 2023 Q2 | 108.65 Million SEK | -30.91% |
| 2023 Q1 | 157.27 Million SEK | -1.21% |
| 2023 Q4 | 96.23 Million SEK | -28.99% |
| 2023 Q3 | 135.52 Million SEK | 24.72% |
| 2022 Q2 | 108.46 Million SEK | 3.19% |
| 2022 Q3 | 104.12 Million SEK | -4.0% |
| 2022 FY | - SEK | 39.93% |
| 2022 Q1 | 105.11 Million SEK | 80.4% |
| 2022 Q4 | 159.19 Million SEK | 52.89% |
| 2021 Q4 | 58.26 Million SEK | -20.65% |
| 2021 FY | - SEK | 12.96% |
| 2021 Q1 | 74.63 Million SEK | 46.39% |
| 2021 Q2 | 74.75 Million SEK | 0.17% |
| 2021 Q3 | 73.43 Million SEK | -1.77% |
| 2020 Q4 | 50.98 Million SEK | 58.66% |
| 2020 Q1 | 60.35 Million SEK | -16.56% |
| 2020 Q2 | 105.36 Million SEK | 74.58% |
| 2020 Q3 | 32.13 Million SEK | -69.5% |
| 2020 FY | - SEK | -3.75% |
| 2019 Q3 | 53.57 Million SEK | -34.92% |
| 2019 FY | - SEK | -9.46% |
| 2019 Q1 | 50.3 Million SEK | -35.01% |
| 2019 Q4 | 72.33 Million SEK | 35.01% |
| 2019 Q2 | 82.32 Million SEK | 63.66% |
| 2018 Q2 | 81.8 Million SEK | 40.38% |
| 2018 Q4 | 77.4 Million SEK | 16.25% |
| 2018 FY | - SEK | 16.53% |
| 2018 Q1 | 58.26 Million SEK | -16.24% |
| 2018 Q3 | 66.58 Million SEK | -18.6% |
| 2017 Q1 | 57.39 Million SEK | 19.15% |
| 2017 Q4 | 69.56 Million SEK | 25.49% |
| 2017 Q3 | 55.43 Million SEK | -11.51% |
| 2017 FY | - SEK | 21.26% |
| 2017 Q2 | 62.64 Million SEK | 9.15% |
| 2016 Q4 | 48.17 Million SEK | 1.23% |
| 2016 Q2 | 53.86 Million SEK | 13.89% |
| 2016 Q1 | 47.29 Million SEK | 77.84% |
| 2016 FY | - SEK | 28.66% |
| 2016 Q3 | 47.59 Million SEK | -11.65% |
| 2015 Q1 | 57.16 Million SEK | 127.8% |
| 2015 FY | - SEK | -19.38% |
| 2015 Q4 | 26.59 Million SEK | -6.11% |
| 2015 Q3 | 28.32 Million SEK | -37.03% |
| 2015 Q2 | 44.98 Million SEK | -21.31% |
| 2014 Q2 | 23.76 Million SEK | -81.15% |
| 2014 Q3 | 19.89 Million SEK | -16.31% |
| 2014 Q4 | 25.09 Million SEK | 26.14% |
| 2014 Q1 | 126.06 Million SEK | 540.43% |
| 2014 FY | - SEK | 128.14% |
| 2013 FY | - SEK | -80.37% |
| 2013 Q2 | 28.62 Million SEK | 19.19% |
| 2013 Q4 | 19.68 Million SEK | 10.76% |
| 2013 Q3 | 17.77 Million SEK | -37.9% |
| 2013 Q1 | 24.01 Million SEK | 70.32% |
| 2012 Q4 | 14.09 Million SEK | -4.99% |
| 2012 Q3 | 14.83 Million SEK | -28.57% |
| 2012 Q2 | 20.77 Million SEK | -94.62% |
| 2012 Q1 | 386.19 Million SEK | 1156.41% |
| 2012 FY | - SEK | 301.78% |
| 2011 Q4 | 30.73 Million SEK | 27.21% |
| 2011 Q1 | 26.82 Million SEK | -15.09% |
| 2011 Q2 | 37.89 Million SEK | 41.25% |
| 2011 Q3 | 24.16 Million SEK | -36.23% |
| 2011 FY | - SEK | 49.1% |
| 2010 Q1 | 14.81 Million SEK | -18.9% |
| 2010 Q3 | 8.97 Million SEK | -50.52% |
| 2010 FY | - SEK | 26.7% |
| 2010 Q2 | 18.12 Million SEK | 22.35% |
| 2010 Q4 | 31.59 Million SEK | 252.22% |
| 2009 Q2 | 17.13 Million SEK | 19.45% |
| 2009 Q1 | 14.34 Million SEK | 0.0% |
| 2009 FY | - SEK | 65.4% |
| 2009 Q4 | 18.26 Million SEK | 143.91% |
| 2009 Q3 | 7.49 Million SEK | -56.28% |
| 2008 Q2 | 5.18 Million SEK | 0.0% |
| 2008 FY | - SEK | 135.07% |
| 2007 FY | - SEK | 102.57% |
| 2006 FY | - SEK | 147.31% |
| 2005 FY | - SEK | -155.13% |
| 2004 FY | - SEK | 42.3% |
| 2003 FY | - SEK | -58.61% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 3505.084% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 1331.092% |
| Enzymatica AB (publ) | -41.12 Million SEK | 1233.675% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 1182.828% |
| Gabather AB (publ) | 37 Thousand SEK | -1259872.973% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 3256.33% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 1829.234% |
| Nanexa AB (publ) | -70.79 Million SEK | 758.544% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | 3877.877% |
| ODI Pharma AB | 1.36 Million SEK | -33994.092% |
| Orexo AB (publ) | -22 Million SEK | 2219.045% |
| Probi AB (publ) | 115.61 Million SEK | -303.237% |
| Swedencare AB (publ) | 484 Million SEK | 3.68% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 93.556% |
| Toleranzia AB | -7.39 Million SEK | 6401.568% |
| Vivesto AB | -89.75 Million SEK | 619.385% |